Literature DB >> 6732214

Disposition of phosphomycin in patients with pleural effusion.

C F Lastra, E L Mariño, M Barrueco, M S Gervós, A D Gil.   

Abstract

The pharmacokinetics of phosphomycin were studied in seven patients with pleural effusion of varied etiologies. All patients received a single intravenous bolus of 30 mg of antibiotic per kg. Phosphomycin levels in plasma and pleural fluid were determined simultaneously. Antibiotic levels in plasma followed a two-compartment open kinetic model. In the pleural fluid, maximum concentrations of phosphomycin, 42.63 +/- 16.03 micrograms/ml (mean +/- standard deviation), were reached at 3.69 +/- 1.08 h after administration of the antibiotic. The disappearance constant of the antibiotic from the pleural fluid was significantly smaller (0.16 +/- 0.06 h-1) than the elimination constant determined from the levels of drug in plasma (0.73 +/- 0.26 h-1). Phosphomycin persisted in antibacterial concentrations in the pleural fluid for a considerable period of time. The low accessibility of phosphomycin observed in one of the patients in the study, with a maximum concentration value of 2.16 micrograms of phosphomycin per ml of pleural fluid, could be due to the existence of pachypleuritis in that patient; this was later confirmed in clinical and histological studies done after the research described here.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6732214      PMCID: PMC185552          DOI: 10.1128/AAC.25.4.458

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Pharmacokinetics of phosphonomycin in Man. I. Intravenous administration.

Authors:  K C Kwan; D A Wadke; E L Foltz
Journal:  J Pharm Sci       Date:  1971-05       Impact factor: 3.534

2.  Phosphonomycin, a new antibiotic produced by strains of streptomyces.

Authors:  D Hendlin; E O Stapley; M Jackson; H Wallick; A K Miller; F J Wolf; T W Miller; L Chaiet; F M Kahan; E L Foltz; H B Woodruff; J M Mata; S Hernandez; S Mochales
Journal:  Science       Date:  1969-10-03       Impact factor: 47.728

3.  Enteropathogenic E. coli gastroenterocolitis in neonates treated with fosfomycin.

Authors:  C G Taylor; E Mascarós; J Román; M Paz; M Santos; A Muñoz; M Gobernado
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

4.  Treatment of respiratory infections with fosfomycin.

Authors:  R Bacardí; J Tornos; I Moga; N Martí; P Alomar; L Gaztelurrutia; C Villalonga
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

5.  Cefotaxime in bronchopulmonary infections--a clinical and pharmacological study.

Authors:  H Lode; B Kemmerich; G Gruhlke; G Dzwillo; P Koeppe; I Wagner
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

6.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

7.  Penetration of cefuroxime and doxycycline into the pleural fluid.

Authors:  B Hoffstedt; B Ode; M Walder; A Hanson; P Christensson; S Cronberg
Journal:  J Antimicrob Chemother       Date:  1980-01       Impact factor: 5.790

8.  Disposition of cefoxitin in patients with pleural effusion.

Authors:  M Barrueco; M J Garcia; M J Otero; A Dominguez-Gil; J M de Letona
Journal:  Clin Ther       Date:  1981       Impact factor: 3.393

9.  Concentrations of ampicillin in pleural fluid and serum after single and repetitive doses of bacampicillin.

Authors:  W Bronsveld; J Stam; D M MacLaren
Journal:  Scand J Infect Dis Suppl       Date:  1978

10.  Fosfomycin in chronic urinary infections.

Authors:  A Allona; J A Díaz Cabrera; P Manchado
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

View more
  2 in total

Review 1.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

2.  Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods.

Authors:  L V Perdigão-Neto; M S Oliveira; C F Rizek; C M D M Carrilho; S F Costa; A S Levin
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.